Lionello Marco, Blandamura Stella, Staffieri Claudia, Tealdo Giulia, Giacomelli Luciano, Marchese Ragona Rosario, de Filippis Cosimo, Staffieri Alberto, Marioni Gino
Department of Neurosciences, Otolaryngology Section, University of Padova, Padova, Italy.
Department of Medicine, DIMED, University of Padova, Padova, Italy.
Am J Otolaryngol. 2015 Mar-Apr;36(2):184-9. doi: 10.1016/j.amjoto.2014.10.027. Epub 2014 Oct 22.
Reported outcomes of postoperative radiotherapy (PORT) for laryngeal squamous cell carcinoma (LSCC) have varied and sometimes been disappointing. The aim of the present preliminary study was to investigate whether a given immunohistochemical pattern of Maspin expression in laryngeal carcinoma cells could be prognostically associated with response to PORT.
Thirty-two consecutive patients treated for LSCC with primary surgery and PORT. The subcellular (nuclear vs non-nuclear) pattern of Maspin expression was assessed immunohistochemically on LSCC surgical specimens and analyzed in relation to recurrence rate (RR) and disease-free survival (DFS).
A non-nuclear Maspin expression was found in 23 of 32 cases (72%), and all recurrences (17 cases) occurred in this subgroup of patients. A non-nuclear Maspin expression was strongly associated with recurrence [p = 0.0002, hazard ratio (HR) 5.58] and a shorter DFS (p = 0.0004) after PORT for LSCC. Even in N0 patients, a non-nuclear Maspin expression was associated with a significantly higher RR (p = 0.04, HR 1.42) and a shorter DFS (p = 0.02). Among the common clinic-pathological parameters considered, only N stage showed a trend toward an association with prognosis in terms of DFS (p = 0.08).
Assessing subcellular patterns of Maspin expression in LSCC specimens could identify patients less likely to respond to PORT, who might benefit from combined chemo-radiotherapy to improve the efficacy of adjuvant protocols.
喉鳞状细胞癌(LSCC)术后放疗(PORT)的报告结果各不相同,有时令人失望。本初步研究的目的是调查喉癌细胞中特定的Maspin免疫组化表达模式是否与PORT反应存在预后相关性。
32例连续接受LSCC原发手术和PORT治疗的患者。在LSCC手术标本上通过免疫组化评估Maspin表达的亚细胞(核与非核)模式,并分析其与复发率(RR)和无病生存期(DFS)的关系。
32例中有23例(72%)发现非核Maspin表达,所有复发(17例)均发生在该亚组患者中。LSCC接受PORT后,非核Maspin表达与复发密切相关[p = 0.0002,风险比(HR)5.58]以及较短的DFS(p = 0.0004)。即使在N0患者中,非核Maspin表达也与显著更高的RR(p = 0.04,HR 1.42)和较短的DFS(p = 从考虑的常见临床病理参数来看,仅N分期在DFS方面显示出与预后相关的趋势(p = 0.08)。
评估LSCC标本中Maspin表达的亚细胞模式可以识别出对PORT反应较差的患者,这些患者可能从联合放化疗中获益,以提高辅助治疗方案的疗效。 02)相关。